Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Long-term coronary heart disease study with niacin tablets, simvastatin begun
August 4th, 2005
Kos Pharmaceuticals, Inc. (KOSP) announced the commencement of a study to evaluate whether combination therapy with Kos' Niaspan (niacin extended-release tablets) and simvastatin is superior to simvastatin alone in preventing cardiovascular events, such as heart attack, stroke and acute coronary syndromes. The study, entitled "Atherothrombosis Intervention in Metabolic Syndrome with Low HDL-C/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH)," is the first large-scale study using combination therapy with Niaspan and simvastatin to evaluate whether there is a benefit of treating low HDL-C (high-density lipoprotein cholesterol or "good" cholesterol) levels...
Source: Women's Health Weekly (2005-08-04)
|
